[ad_1] MUNICH – The combination of avelumab and axitinib has dramatically improved SSP compared to standard sunitinib in patients with advanced and untreated renal cell carcinoma, according to the results of the …
Read More »[ad_1] MUNICH – The combination of avelumab and axitinib has dramatically improved SSP compared to standard sunitinib in patients with advanced and untreated renal cell carcinoma, according to the results of the …
Read More »